56%
SKYRIZI
Percentage of patients
SKYRIZI vs 2 Pills
SKYRIZI VS OTEZLA
In a study of 352 patients comparing SKYRIZI to Otezla
11x higher percentage of patients achieved 90% clearer skin on SKYRIZI at 16 weeks
5%
Otezla
Percentage of patients
This 1-year (52-week) study compared SKYRIZI to Otezla for the treatment of adults with moderate plaque psoriasis who qualify for oral medications or biologics. It was a 2-part study set up to evaluate the effectiveness of SKYRIZI and Otezla at 16 weeks and 1 year. Overall safety was observed throughout the study.
Patients were aware of the treatments they were taking, which may have influenced results.
OTEZLA® is a registered trademark of Amgen Inc.
SKYRIZI VS SOTYKTU
In a study of 393 patients comparing SKYRIZI to Sotyktu
>2x higher percentage of patients achieved 90% clearer skin on SKYRIZI at 16 weeks
57%
SKYRIZI
Percentage of patients
23%
Sotyktu
Percentage of patients
This 1-year (52-week) study compared SKYRIZI to Sotyktu for the treatment of adults with moderate plaque psoriasis who have not taken a biologic before and qualify for oral medications or biologics. It was a 2-part study set up to evaluate the effectiveness of SKYRIZI and Sotyktu at 16 weeks and 1 year. Overall safety was observed throughout the study.
Patients were aware of the treatments they were taking, which may have influenced results.
SOTYKTU® is a registered trademark of Bristol-Myers Squibb Company.
SEE HOW PEOPLE RESPONDED TO A TREATMENT SATISFACTION QUESTIONNAIRE ABOUT SKYRIZI
In 2 separate studies, patients were given a treatment satisfaction questionnaire with a total of 9 questions across 3 categories. In Study 1 of SKYRIZI and Otezla with 110 participants, those on SKYRIZI responded to a treatment satisfaction questionnaire about SKYRIZI. In Study 2 of SKYRIZI and Sotyktu with 127 participants, those on SKYRIZI responded to a treatment satisfaction questionnaire about SKYRIZI. Ask your dermatologist about the treatment satisfaction questionnaire.
Average patient-reported treatment satisfaction scores for SKYRIZI at Week 16*
In these studies, patients were aware of the treatments they were taking, which may have influenced results. TSQM-9 data were not completed by all patients in the studies. Data presented here were the data available at 16 weeks.
*Scores are based on the 9-item Treatment Satisfaction Questionnaire (TSQM-9).
OTEZLA® is a registered trademark of Amgen Inc.
SOTYKTU® is a registered trademark of Bristol-Myers Squibb Company.
SIDE EFFECTS
SKYRIZI AND OTEZLA
Most common side effects at 16 weeks in this study
- Otezla: Diarrhea, nausea, COVID-19, and headache.
- SKYRIZI: COVID-19.
Most common side effects through 1 year were consistent with those at 16 weeks and also included nasopharyngitis (inflammation of the nasal passages and the throat) and upper respiratory tract infections for SKYRIZI and nasopharyngitis for Otezla.
OTEZLA® is a registered trademark of Amgen Inc.
SKYRIZI AND SOTYKTU
Most common side effects at 16 weeks in this study
- Sotyktu: Nasopharyngitis and upper respiratory tract infections.
- SKYRIZI: Nasopharyngitis and upper respiratory tract infections.
Side effects will be assessed throughout this 1-year study.
SOTYKTU® is a registered trademark of Bristol-Myers Squibb Company.
These 2 separate studies were not designed to make conclusions about safety. These are not all the possible side effects of SKYRIZI, Otezla, or Sotyktu. How frequently these side effects occur may change with longer treatment. Refer to the medication guide of each product to talk to your doctor about the benefits and risks of these medications. See Important Safety Information for more about the safety of SKYRIZI.
